SynAct Pharma AB (OSTO:SYNACT) Treasury Stock : kr0.00 Mil (As of Sep. 2024)

View and export this data going back to 2016. Start your Free Trial

What is SynAct Pharma AB Treasury Stock?

Treasury stock is the portion of shares that a company keeps in their own treasury. SynAct Pharma AB's treasury stock for the quarter that ended in Sep. 2024 was kr0.00 Mil.

Treasury stock may have come from a repurchase or buyback from shareholders; or it may have never been issued to the public in the first place.

SynAct Pharma AB Treasury Stock Historical Data

The historical data trend for SynAct Pharma AB's Treasury Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

SynAct Pharma AB Treasury Stock Chart

SynAct Pharma AB Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Treasury Stock

Get a 7-Day Free Trial

SynAct Pharma AB Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Treasury Stock	Get a 7-Day Free Trial															-	-	-	-	-

SynAct Pharma AB Treasury Stock Calculation

The portion of shares that a company keeps in their own treasury. Treasury stock may have come from a repurchase or buyback from shareholders; or it may have never been issued to the public in the first place. These shares don't pay dividends, have no voting rights, and should not be included in shares outstanding calculations.

SynAct Pharma AB Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » SynAct Pharma AB (OSTO:SYNACT) » Definitions » Treasury Stock

Comparable Companies

Traded in Other Exchanges

8F8:Germany

Address

Sheelevagen 2, Lund, SWE, 223 81

Website

https://www.synactpharma.se

SynAct Pharma AB is a clinical-stage biotech company focused on resolving inflammation through selective activation of the melanocortin system. The company has a platform technology based on a new class of drug candidates that target acute exacerbations in chronic inflammatory diseases with the primary aim of stimulating natural healing mechanisms. AP1189, the company's lead drug candidate, is being evaluated in three Phase 2 clinical programs regarding rheumatoid arthritis, idiopathic membranous glomerulonephritis and virus-induced respiratory failure.

SynAct Pharma AB Headlines

No Headlines